cco retroviruses_2013_art_slides
Post on 07-May-2015
23.457 Views
Preview:
DESCRIPTION
TRANSCRIPT
March 3-6, 2013Atlanta, Georgia
Highlights of Atlanta 2013: ART as Treatment and PreventionCCO Independent Conference Coverageof the 2013 Conference on Retroviruses and Opportunistic Infections*
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
This program is supported by educational grants from
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
About These Slides
Users are encouraged to use these slides in their own noncommercial presentations, but we ask that content and attribution not be changed. Users are asked to honor this intent
These slides may not be published or posted online without permission from Clinical Care Options (email permissions@clinicaloptions.com)
DisclaimerThe materials published on the Clinical Care Options Web site reflect the views of the authors of the CCO material, not those of Clinical Care Options, LLC, the CME providers, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
Faculty
Joel E. Gallant, MD, MPHProfessor of Medicine and Epidemiology Associate Director, Johns Hopkins AIDS ServiceDivision of Infectious DiseasesJohns Hopkins University School of MedicineBaltimore, Maryland
Kathleen E. Squires, MDProfessor of Medicine Director, Division of Infectious DiseasesJefferson Medical CollegeThomas Jefferson UniversityPhiladelphia, Pennsylvania
Andrew R. Zolopa, MDAssociate Professor of MedicineDirector, Stanford Positive Care ProgramPrincipal Investigator, Stanford AIDS Clinical Trials UnitStanford University School of MedicineStanford, California
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
Disclosures
Joel E. Gallant, MD, MPH, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and Takara Bio and funds for research support from Gilead Sciences.
Kathleen E. Squires, MD, has disclosed that she has received funds for research support from Biocryst, Gilead Sciences, Merck, and Vertex; has served on advisory boards for Abbott, Gilead Sciences, Janssen, Merck, Tobira, and ViiV; has received consulting fees from Tobira; and has served on a data and safety monitoring board for Pfizer.
Andrew R. Zolopa, MD, has disclosed that he has received funds for research support from Gilead Sciences, Pfizer, and Vertex and consulting fees from Bristol-Myers Squibb, Gilead Sciences, and Janssen.
DHHS Guideline Update
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
2013 Update: DHHS Guidelines on ART for HIV-Infected Adults and Adolescents ART is recommended for all HIV-infected, ART-naive pts to reduce
risk of disease progression and transmission
– Strength of recommendation varies by CD4+ cell count and risk group (perinatal, heterosexual, other)
– Pts should be ready to commit to ART and understand benefits and risks of therapy and importance of adherence; individual pts may elect to defer ART
Regarding alternative regimens for ART-naive patients
– RPV-based regimens recommended alternatives only for patients with baseline HIV-1 RNA ≤ 100,000 copies/mL
– Fixed-dose EVG/COBI/TDF/FTC recommended for patients with CrCl > 70 mL/min
– 3-NRTI regimens no longer recommendedDHHS Guidelines. February 2013.
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
2013 Update: DHHS Guidelines on ART for HIV-Infected Adults and Adolescents Pts failing INSTI-based regimens should undergo genotypic
assay for INSTI resistance to determine future utility of class
Genotypic tropism assay now available as potential alternative test prior to initiating CCR5 antagonist regimens
Patients with early infection should be offered ART
– “Early” HIV infection now refers to acute (after infection, prior to seroconversion) and recent (< 6 mos) infections
EFV may be continued in pregnant women with virologic suppression
New data on roles/mechanisms of RTV and COBI as pharmacokinetic enhancers
DHHS Guidelines. February 2013.
Cure Research
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
Very Early Triple-Drug ART Elicits “Functional Cure” in HIV-Infected Child Infant born to untreated HIV-infected mother at 35 wks’
gestation via spontaneous vaginal delivery[1]
– Maternal HIV infection identified during labor via ELISA and Western blot
– Infant HIV infection confirmed via HIV-1 DNA PCR, HIV-1 RNA analysis of 2 separate samples at 30 and 31 hrs of age[2]
– ZDV/3TC + NVP (at therapeutic dose) initiated at 31 hrs of age, continued for 7 days
– ZDV/3TC + LPV/RTV continued from 7 days to 18 mos of age
– HIV-1 RNA undetectable by Day 30
– Mother removed patient from care at 18 mos of age
1. Persaud D, et al. CROI 2013. Abstract 48LB. 2. DHHS Pediatric Guidelines. 2012.
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
“Functional Cure” Child: Standard HIV-1 Assays Undetectable to Age 26 Mos
Assessments at Mos 24 and 26
– Western blot negative
– No HIV-specific CD8+ or CD4+ T-cell responses
– Standard HIV-1 RNA and HIV-1 DNA undetectable
– By ultrasensitive assays
– Mo 24: HIV-1 RNA 1 c/mL; HIV-1 DNA < 2.7 c/million PBMCs
– Mo 26: HIV-1 DNA 4 c/million PBMCs
Clinical trials of exposed infants treated with ART recommended
Persaud D, et al. CROI 2013. Abstract 48LB.
ART regimens: ZDV/3TC + NVP (31 hours – 7 days)
ZDV/3TC + LPV/RTV (7 days – 18 months)
Plasma VL on ART displayed typical biphasic decay from baseline VL 19,812 c/mL
– VL undetectable by < 30d of age
– VL remained undetectable though > 80d of age
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
Early Treatment of Pts With Acute HIV Infection Restricts Seeding of Reservoirs RV254/SEARCH 010: ongoing, prospective, open-label study of subjects
seeking voluntary HIV testing (n = 75 with Fiebig stage I-III acute infection)
Before ART, HIV reservoir seeding limited
– Integrated HIV-1 DNA undetectable in PBMCs (92%) and sigmoid colon (88%) of most Fiebig I pts
– Lower infection frequencies of central memory CD4+ T cells vs other memory cells
After ART, decline in HIV reservoir size
– Integrated HIV-1 DNA undetectable in PBMCs in 90% of pts at 1 yr
– Reservoir primarily in transitionaland effector memory CD4+ T cells
Suggests very early ART may prevent seeding of reservoirs
Fiebig Stages
Fiebig I: RNA+, p24R neg, 3rd-gen ELISA neg
– Would not be detected by 4th-gen ELISA
Fiebig II: RNA+, p24+, 3rd-gen ELISA neg
Fiebig III: 3rd-gen ELISA+, WB neg
Ananworanich J, et al. CROI 2013. Abstract 47.
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
Vorinostat Activates HIV Transcription in Latently Infected CD4+ T Cells Vorinostat investigated as possible
strategy to eliminate latent HIV infection in pts on stable ART
– Histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
– Single dose ↑ HIV-1 RNA expression in resting memory CD4+ cells of HIV-infected patients
– Activation may result in elimination of latently infected T cells
Current study is a single-arm trial of vorinostat 400 mg QD for 14 days (N = 20) in pts on stable ART, CD4+ count > 500 cells/mm3
18/20 pts had significant increase in cell-associated unspliced HIV-1 RNA on ≥ 2 occasions while on drug
– Mean 2.65-fold increase
All AEs mild (grade 1/2)
– Most common: diarrhea, lethargy, thrombocytopenia, dysgeusia
No significant changes in HIV-1 DNA in PBMCs or rectal tissue
– Suggests vorinostat alone not likely to eliminate latent infected cells
Elliott EJ, et al. CROI 2013. Abstract 50LB.
PrEP
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
PrEP Trials to Date
Trial Population/Setting InterventionReduction in
HIV Infection Rate, %
CAPRISA[1]
(N = 899)High-risk women in
South Africa Coitally applied
vaginal TFV gel39
iPrEX[2] (N = 2499)
MSM, transgender women, 11 sites in US, South America,
Africa, Thailand Daily oral TDF/FTC 44
Partners PrEP[3] (N = 4747)
Serodiscordant couples in Africa
Daily oral TDF Daily oral TDF/FTC
Women: 71; men: 63 Women: 66; men: 84
TDF2[4]
(N = 1219)Heterosexual males and
females in Botswana Daily oral TDF/FTC 62*
FEM-PrEP[5]
(N = 2120)High-risk women in Africa Daily oral TDF/FTC
Equal numbers of infections in active and control arms
Study stopped for lack of efficacy
1. Abdool Karim Q, et al. Science. 2010;329:1168-1174. 2. Grant RM, et al. N Engl J Med. 2010;363: 2587-2599. 3. Baeten JM, et al. N Engl J Med. 2012;367:399-410. 4. Thigpen MC, et al. N Engl J Med. 2012;367:423-434. 5. Van Damme L, et al. N Engl J Med. 2012;367:411-422.
*Underpowered to detect differences between sexes
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
VOICE: Oral TDF, Oral TDF/FTC, Vaginal TFV Gel as PrEP in African Women Phase IIB placebo-controlled trial of > 5000 women in South Africa, Uganda,
and Zimbabwe of daily oral TDF, daily oral TDF/FTC, daily vaginal TFV 1% gel as PrEP
– DSMB stopped daily oral TDF arm in September 2011 and daily vaginal gel arm in November 2011, both for lack of efficacy; daily oral TDF/FTC arm continued
– 334 infections seen across 5 arms; 22 infected at enrollment
Primary Efficacy Results (mITT)
TDF*(n = 1007)
Oral Placebo*
TDF/FTC(n = 1003)
Oral Placebo
TFV Gel(n = 1007)
GelPlacebo
Infections, n 52 35 61 60 61 70
Infections/100 PY 6.3 4.2 4.7 4.6 5.9 6.8
Protective Efficacy vs Placebo
HR (95% CI) 1.49 (0.97-2.30) 1.04 (0.7-1.5) 0.85 (0.6-1.2)
P value .07 > .2 > .2
*Censored when sites took women off TDF and TDF placebo. Total n = 1009.Marrazzo J, et al. CROI 2013. Abstract 26LB.
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
VOICE: Lack of Detectable TFV in Plasma; High Rate of Infection in Younger Women
Despite high self-reported adherence, < 40% of women had detectable plasma TFV at first study visit
TFV detected in mean of ≤ 30% of samples in each arm
– ≥ 50% of women in each arm had no TFV detected in any sample
TFV detection less likely if unmarried, younger than 25 yrs, partner younger than 28 yrs
– Highest rates of HIV acquisition in unmarried, younger than 25 yrs
Marrazzo J, et al. CROI 2013. Abstract 26LB. Graphic used with permission.
Pts
Wit
h D
etec
tab
le T
FV
* (%
) 100
80
60
40
20
1 2 3 4 5 6
TDF/FTCTDFTFV 1% gel
TDF/FTCTDF TFV 1%
0
123119156
11180
107
1175682
952852
611630
Quarterly Visits
Plasma TFV Detection in Random Cohort Sample
*Level of TFV detection: ≥ 0.3 ng/mL.
Pts at Risk, n
135147166
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
Additional Data on PrEP
GSK1265744, dolutegravir analogue packaged in nanoparticles (GSK744LAP), permitting monthly or quarterly dosing in humans by IM injection
– 8/8 macaques injected with GSK744LAP and rectally challenged with SHIV protected from infection; 8/8 controls became infected (P < .0001)[1]
Intravaginal rings containing TDF protected against SHIV infection in 6/6 macaques; 11/12 controls became infected (P < .0004)[2]
Among iPrEX participants stopping PrEP before entry into open-label extension (iPrEX OLE), incidence of HIV similar among participants originally on TDF/FTC PrEP and those originally on placebo (P = .43)[3]
– Similarities indicate that although high-risk behaviors continued, there was lack of compensatory increase in high-risk behavior after PrEP discontinued
– HIV incidence after stopping PrEP remained high
1. Andrews C, et al. CROI 2013. Abstract 24LB. 2. Smith J, et al. CROI 2013. Abstract 25LB. 3. Grant R, et al. CROI 2013. Abstract 27.
Antiretroviral Therapy Trials:Current Agents
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
SAILING: Dolutegravir vs Raltegravir in ART-Exp’d, Integrase Inhibitor–Naive Pts Phase III randomized, double-blind, double-dummy,
noninferiority study
Pozniak A, et al. CROI 2013. Abstract 179LB.
Treatment-experienced, integrase inhibitor–naive patients with HIV-1 RNA
> 400 copies/mL and ≥ 2 class resistance
(N = 715)
Dolutegravir 50 mg QD + OBR(n = 354)
Raltegravir 400 mg BID + OBR(n = 361)
Stratified by number of fully active background agents, use of DRV,
screening HIV-1 RNA ≤ vs > 50,000 copies/mL
Wk 24 interim analysis Wk 48
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
SAILING: Higher Rate of Virologic Suppression With DTG vs RAL at 24 Wks
Lower incidence of integrase resistance at VF with DTG
– R263K at VF in 2 DTG pts; first report of treatment-emergent resistance on DTG
– < 2-fold change in IC50 for both DTG and RAL
– Y143, Q148, and/or N155 at VF in 9 RAL pts; consistent with previous studies
– High-level resistance to RAL
Both regimens well tolerated with similar AE profiles
Pozniak A, et al. CROI 2013. Abstract 179LB. Graphic used with permission.
HIV
-1 R
NA
< 5
0 co
pie
s/m
L (
%)
100
80
60
40
20
0BL 4 8 12 16 24
Wk
Wk 24 adjusted difference in response: +9.7 in favor of DTG (95% CI: 3.4% to 15.9%; P = .003)
79%
70%
Dolutegravir + OBRRaltegravir + OBR
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
Dolutegravir Efficacy in Phase III Studies in ART-Naive Pts: Subgroup Analyses Retrospective analysis of phase III trials in treatment-naive pts [1]
– SPRING-2[2]: DTG noninferior to RAL at Wk 48, each combined with investigator-selected NRTIs (TDF/FTC or ABC/3TC)
– SINGLE[3]: DTG + ABC/3TC superior to TDF/FTC/EFV at Wk 48
In both trials, activity of DTG-based regimens similar in subgroup analyses by HIV risk factor, baseline HIV-1 RNA, CD4+ cell count, sex, age, race
In SINGLE, higher rates of HIV-1 RNA < 50 copies/mL with DTG-based therapy across patient subgroups
In both trials, no apparent subgroup differences in AEs or discontinuations
1. Brinson C, et al. CROI 2013. Abstract 554. 2. Raffi F, et al. Lancet. 2013;381:735-743.3. Walmsley S, et al. ICAAC 2012. Abstract H-556b.
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
Subgroup Analyses of SPRING-2 and SINGLE: Virologic Suppression at Wk 48
Brinson C, et al. CROI 2013. Abstract 554. Graphic used with permission.
≤ 100,000 c/mL> 100,000 c/mL< 350 cells/mm3
≥ 350 cells/mm3
FemaleMale
< 50 yrs≥ 50 yrs
WhiteBlack
SPRING-2
0% 50% 100%
DTGRAL
30%20%10%0%-20% -10%
Difference (DTG-RAL) and 95% CI
In favor of RAL In favor of DTG
≤ 100,000 c/mL> 100,000 c/mL< 350 cells/mm3
≥ 350 cells/mm3
FemaleMale
< 50 yrs≥ 50 yrs
WhiteBlack
SINGLE
0% 50% 100%
DTG + ABC/3TCTDF/FTC/EFV
30%20%10%0%-20% -10%
Difference (DTG-EFV) and 95% CIIn favor of DTGIn favor of EFV
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
SECOND-LINE: LPV/RTV + RAL vs LPV/RTV + NRTIs After First-line VF Randomized, open-label, international, multicenter trial
Humphries A, et al. CROI 2013. Abstract 180LB.
Lopinavir/Ritonavir 400/100 mg BID +Raltegravir 400 mg BID
(n = 270)
Lopinavir/Ritonavir 400/100 mg BID + 2-3 NRTIs QD or BID
(n = 271)
HIV-infected pts with virologic failure on first-line
regimen of 2 NRTIs + NNRTI(N = 541)
Stratified by clinical site, baseline HIV-1 RNA
(≤ or > 100,000 copies/mL)
Wk 48 primary endpoint
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
SECOND-LINE: Noninferiority of LPV/RTV + RAL vs LPV/RTV + NRTIs
Pooled pt data from ACTG A5142, A5202, A5208 of those failing first-line boosted PI regimens found 131/200 (66%) remained on same regimen[2]
– Various regimen changes: n = 69
– HIV-1 RNA < 400 c/mL at Wk 24 similar between pts who maintained same regimen and those who switched
– Pts with highest resuppression rates were those with higher CD4+ counts at regimen change and those who had ever responded to first regimen
– Suggests better adherence
0
20
40
80
100
Wk
LPV/RTV + RALLPV/RTV + 2-3 NRTIs
60
0 12 24 36 48
HIV
-1 R
NA
< 2
00 c
/mL
(%
)
Similar high levels of virologic suppression with each strategy in primary mITT analysis[1]
82.6
80.8
P = .59
1. Humphries A, et al. CROI 2013. Abstract 180LB. Graphic used with permission.2. Zheng Y, et al. CROI 2013. Abstract 558.
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
OPTIONS: NRTIs vs No NRTIs in Regimens for Highly ART-Experienced Pts Randomized, noninferiority, multicenter trial (ACTG A5241)
– Primary endpoint: regimen failure (VF or divergence from NRTI assignment, whichever occurred first)
NRTI-Omitting Individualized Optimized Regimen*
(n = 179)
NRTI-Including Individualized Optimized Regimen*
(n = 181)
Treatment-experienced pts failing on PI-based regimen
with NRTI, NNRTI experience and/or resistance
(N = 360)
Stratified by choice of MVC-containing regimen and
previous enfuvirtide or integrase inhibitor experience
*20 potential 3- to 4-drug combinations including DRV/RTV, ENF, ETR, MVC, RAL, TPV/RTV. Individualized selection of regimens with PSS > 2.
Tashima K, et al. CROI 2013. Abstract 153LB.
Yr 1Primary Endpoint
Yr 2Secondary Endpoint
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
OPTIONS: Pt-Specific Regimen Selected Then Randomized to ± NRTI
Tashima K, et al. CROI 2013. Abstract 153LB. Graphic used with permission.
Chosen Regimen and NRTI Combinations Add NRTIsTDF + FTC (3TC)ZDV + TDF + FTC (3TC)Other
RegimenRAL + DRV/RTV + ETRRAL + DRV/RTV + MVCRAL + DRV/RTV + ETR + MVCRAL + ETR + MVCRAL + DRV/RTV + ETR + ENFOther
Randomization
Omit NRTIs
6%
12%
82%6%
56%
7%
8%
14%
9%
Add NRTIs
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
OPTIONS: Omitting NRTIs Noninferior to Adding NRTIs to Optimized Regimen
Similar virologic suppression (HIV-1 RNA < 50 c/mL) in each arm (~ 65%)
Similar CD4+ cell count increases in each arm (90-106 cells/mm3)
No significant difference in any safety outcome when globally evaluating symptoms and laboratory abnormalities
– However, mortality significantly higher in NRTI-added arm (P < .001)
– 6 deaths in NRTI arm, 2 possibly due to ART drug
Tashima KT, et al. CROI 2013. Abstract 153LB. Graphic used with permission.
Primary Efficacy Outcome Comparisons
Outcome, n (%)
Regimen failure
Virologic failure
Stop NRTI assignment
Omit NRTIs(n = 179)
53 (30)
44 (25)
19 (8)
Add NRTIs(n = 181)
48 (26)
45 (25)
10 (6)
-30 -15 0 15 30% Difference (Omit - Add) at 1 Yr (95% CI)
Omitting NRTIsNot Inferior Inferior
3.2 (-6.1 to 12.5)
-0.4 (-9.4 to 8.7)
3.6 (-1.7 to 9.0)
Antiretroviral Therapy Trials:Investigational Agents
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
Tenofovir Alafenamide (TAF) vs Tenofovir DF in ART-Naive Pts TAF (GS-7340), investigational
prodrug of tenofovir with lower plasma concentrations, increased delivery to hepatocytes, lymphoid cells
Randomized, placebo-controlled phase II trial of TAF vs TDF, each coformulated with FTC/EVG/COBI, in ART-naive patients
Zolopa A, et al. CROI 2013. Abstract 99LB. Graphic used with permission.
HIV-infected, ART-naive
patients(N = 170)
TAF/FTC/EVG/COBI(n = 112)
TDF/FTC/EVG/COBI(n = 58)
Wk 48Wk 24Gut
TFV
TDF
TAF
Plasma
TDF/TFV
TAF
Lymphoid Cells
TAF TFV
TFV-MP
TFV-DP
Cathepsin A
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
TAF Noninferior to TDF at Wk 24 Primary Endpoint
Zolopa A, et al. CROI 2013. Abstract 99LB. Graphic used with permission.
TDF/FTC/EVG/COBI
TAF/FTC/EVG/COBI
2 4 8 12 16 24
20
40
60
80
100
HIV
-1 R
NA
< 5
0 c/
mL
(%
)
Wks
0
ITT, M = F Analysis89.7%
87.5%
With TAF:PBMC TFV-DP exposure 5.3 x higher than TDFPlasma TFV exposure 91% lower
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
Change in BMD and Serum Creatinine With TAF vs TDF Smaller change in BMD over 24 wks with TAF vs TDF
Median serum creatinine : TAF 0.07 mg/dL vs TDF 0.12 mg/dL
Zolopa A, et al. CROI 2013. Abstract 99LB. Graphic used with permission.
2
0
-2
Spine
Mea
n %
Ch
ang
e in
BM
D
0 12 24
Wks
-0.8
-2.5P = .002
2
0
-2
Hip
0 12 24
Wks
-0.3
-2.0P < .001
TAF/FTC/EVG/COBI (n = 112)TDF/DTC/EVG/COBI (n = 58)
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
Short-term Efficacy and Tolerability of MK-1439, Investigational QD NNRTI MK-1439, investigational NNRTI,
dosed QD, active against K103N, Y181C, G190A variants
Randomized phase Ib study in ART-naive pts (N = 18; 6 per arm)
– 7-day monotherapy
Similar activity with MK-1439 25 mg vs 200 mg dose
All AEs mild to moderate
– No rash/CNS events
Pharmacokinetics comparable to HIV-negative pts
Anderson M, et al. CROI 2013. Abstract 100. Copyright © 2013 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A. All Rights Reserved.
Ch
ang
e i
n H
IV-1
RN
A (
log
10)
0.3
0.0
-0.3
-0.6
-0.9
-1.2
-1.5
-1.81 2pre 3pre 4pre 5pre 6pre 7pre 724hr
Dayshr From First Dose
Placebo QDMK-1439 25 mg QDMK-1439 200 mg QD
-1.26
-1.37
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
Cenicriviroc: Investigational QD Oral CCR5/CCR2 Receptor Antagonist Randomized, double-blind, double-dummy, dose-finding phase IIb trial
Gathe J, et al. CROI 2013. Abstract 106LB.
ART-naive pts with CCR5-tropic HIV-1, no NRTI or NNRTI
resistance(N = 143)
CVC 100 mg + TDF/FTC (n = 59)
CVC 200 mg + TDF/FTC (n = 56)
EFV 600 mg + TDF/FTC (n = 28)
Wk 48final analysisStratified by BL HIV-1 RNA
< 100,000 or ≥ 100,000 copies/mL
Wk 24primary analysis
Complex dosing: 4 pills with breakfast (4 CVC or 4 CVC placebo or 2 of each); 1 pill on empty stomach at bedtime (EFV or EFV placebo); 1 pill taken anytime (open-label TDF/FTC)
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
Virologic Non-
Response, %
DC Other Than AE,
%
DC Due to AE, %
12 10 0
14 11 2
4 7 18
24-Wk Efficacy and Safety of Cenicriviroc + TDF/FTC vs EFV/TDF/FTC
CVC generally well tolerated with no safety signals
sCD14 decreased with CVC and increased with EFV
Gathe J, et al. CROI 2013. Abstract 106LB. Graphic used with permission..
HIV
-1 R
NA
< 5
0 c/
mL
(%
)
Wks
ITT (FDA Snapshot Analysis)
CVC 100CVC 200EFV
100
80
60
40
20
0BL 4 8 12 16 24201 2
76
73
71
020
324
1145
251712
372816
443318
424019
454120
CVC 100 CVC 200EFV
Pts at Risk, n
Additional Data on Epidemiology and
Antiretroviral Trends
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
ART Initiation Associated With Better Retention in Care in Zambia National ART program at 18
primary care sites in urban Zambia
– ART started when CD4+ cell count < 200 cells/mm³ or WHO stage IV or WHO stage III and CD4+ cell count < 350 cells/mm3
– “Immediate” initiation defined as within 180 days of eligibility; lost to follow-up (LTFU) as ≥ 60 days late
ART started by 75% of 6419 eligible pts with CD4+ 175-225 cells/mm³ and WHO Stage I-II disease
Proportion lost to follow-up greater in those who delayed ART vs those who started ART immediately, P < .001
Pts who started therapy 4x more likely to be retained in care
Factors Associated with LTFU
Adjusted Hazard Ratio (95% CI)
Did not start ART 4.13 (3.69-4.62)
Age 25 yrs or younger
1.85 (1.65-2.07)
CD4+ 175-199 1.16 (1.05-1.29
WHO Stage II 0.82 (0.74-0.90)
Li M, et al. CROI 2013. Abstract 93.
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
Trends in Genotypic Drug Resistance
Among 1484 ART-naive pts in HOPS cohort, GT testing rate increased from 20.8% in 1999-2002 to 62.8% in 2009-2011[1]
– > 1/3 still not tested in most recent period
No statistically significant increase in transmitted resistance from 1999-2011
– Increased frequency of resistance in black, Hispanic, pts with CD4+ > 500 cells/mm3
17.5% of pts had any major IAS-USA mutation in 2009-2011 (similar to CDC analysis)[2]
– Rates of class resistance: NRTI 10.8%; NNRTI 6.6%; PI 1.8%
Separate study showed major INSTI mutations in 1/5 of pts tested since availability of INSTI GT assay[3]
Additional study showed low rates of DRV resistance among all isolates tested that declined over time[4]
1. Buchacz K, et al. CROI 2013. Abstract 615. 2. Kim D, et al. CROI 2013. Abstract 149. 3. Hurt CB, et al. CROI 2013. Abstract 591. 4. Lathouwers E, et al. CROI 2013. Abstract 590.
clinicaloptions.com/hivClinical Impact of New Data From Atlanta 2013
ART and Birth Defects in ANRS French Perinatal Cohort French national prospective
multicenter cohort studying PMTCT strategies in HIV-positive women[1]
– N = 17,000 (~ 70% of HIV-positive women in France)
– 13,124 live births exposed to ART in utero
In EFV first trimester-exposed infants, risk for neurologic (but not neural tube) defects but not for overall birth defects
In ZDV first-trimester-exposed infants, risk for both overall birth defects and heart defects
Findings inconsistent with meta-analysis of studies of EFV use[2] in pregnancy and data from the US Antiretroviral Pregnancy Registry[3]
– Both indicate no risk of birth defect with EFV; APR shows no risk with ZDV
Defects With First Trimester Exposure, AOR (95% CI)
EFV(n = 372)
ZDV(n = 3267)
Overall birth defects
1.3 (0.9-1.9) P = .31
1.4 (1.1-1.8) P = .002
Specific organ system defects
3.2 (1.1-9.1) P = .03
2.5 (1.6-4.2) P = .001
1. Siubide J, et al. CROI 2013. Abstract 81. 2. Ford N, et al. AIDS. 2011;25:2301-2304. 3. Antiretroviral Pregnancy Registry. December 2012.
Go Online for More CCO Coverage of CROI 2013!
Capsule Summaries of key studies
Additional downloadable slideset on Coinfection and Comorbidities
Coming soon! CME-certified slidesets with expert faculty commentary on all key studies
clinicaloptions.com/atlanta2013
top related